Synovial Sarcoma Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Adaptimmune Therapeutics, Advenchen Laboratories, Takara Bio, OncoTherapy Science

DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Synovial Sarcoma, historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Synovial Sarcoma Market Share @ Synovial Sarcoma Market Outlook- https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Synovial Sarcoma Market Research Report
• In March 2025, Adaptimmune announced a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .
• In March 2025, Epizymen Inc., announced study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Soft tissue cancers are rare and can occur almost anywhere in the body. Part 1 of this trial will study the safety and the level that adverse effects of the study drug tazemetostat in combination with doxorubicin (current front line treatment) can be tolerated (known as tolerability).
• Among the 7MM, the US accounted for the highest Synovial Sarcoma Incident Cases in 2023, with around 650 cases; these cases are expected to increase during the forecast period.
• In 2023, the total number of Synovial Sarcoma Incident Cases in EU4 and the UK was highest in Germany, while the lowest number of cases was in Spain.
• In cases of gender-specific Synovial Sarcoma, males are observed to be the predominant contributors compared to females.
• As per DelveInsight's estimates, the highest incidence of Synovial Sarcoma in Japan is in Stage II which has ~100 cases in 2023 that are projected to increase during the forecast period.
• The leading Synovial Sarcoma Companies Adaptimmune Therapeutics, Advenchen Laboratories, Takara Bio, OncoTherapy Science, and others.
• Promising Synovial Sarcoma Pipeline Therapies such as CFT8634, FHD-609, Afamitresgene autoleucel, AL3818, Itacitinib, CAB-AXL-ADC, TP-1287, APX005M, Tazemetostat, and others.

Stay ahead in the Synovial Sarcoma Therapeutics Market with DelveInsight's Strategic Report @ Synovial Sarcoma Market Outlook- https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Synovial Sarcoma Epidemiology Segmentation in the 7MM
• Synovial Sarcoma Incident Cases
• Synovial Sarcoma Gender-specific Cases
• Synovial Sarcoma Age-specific Cases
• Synovial Sarcoma Location-specific Cases
• Synovial Sarcoma Stage-specific Case
• Antigens-specific (MAGE-A4, NY-ESO-1, PRAME, and others) Cases
• Treated Patient Pool in First-line Setting
• Treated Patient Pool in Secondline and Above (Heavily pretreated)

Download the report to understand which factors are driving Synovial Sarcoma Epidemiology trends @ Synovial Sarcoma Prevalence- https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Synovial Sarcoma Market Dynamics
The synovial sarcoma market dynamics are anticipated to change in the coming years. A wide array of biomarkers linked to synovial sarcoma are presently under investigation to understand their pathways and mechanisms of action. Extensive research conducted on this has significantly contributed to the in-depth study of the disease's pathophysiology, which, in turn, can be leveraged for new drug development. Sarcomas, a diverse group of tumors affecting individuals of all age groups, have created an opportunity for personalized therapy, allowing companies to offer premium services and achieve high profits. Notably, various targeted therapies, such as Letetresgene autoleucel by GSK and ADP-A2M4 by Adaptimmune, both in Phase II development, are anticipated to soon enter the synovial sarcoma market, contributing to its growth.

Synovial Sarcoma Treatment Landscape
The treatment plan for synovial sarcoma is tailored to the individual patient. The type of treatment that is usually depend on size and location of the tumor, the patient's age and overall health, and patient's preference. The goal of the treatment for synovial sarcoma is to cure the cancer. However, not all patients are cured. In some may come back. If the cancer comes back, it may be treated with surgery, radiation therapy, chemotherapy, or targeted therapy. As per latest treatment paradigms chemotherapy regimen is administered for a fixed number of cycles followed by a watchful waiting approach to assess the optimum response. Doxorubicin and Ifosfamideconstitute the first line approach thereby helping generate a large chunk of the revenue.

To learn more about Synovial Sarcoma treatment guidelines, visit @ Synovial Sarcoma Treatment Market Landscape- https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Synovial Sarcoma Drug Market
DelveInsight's analysts estimate that the market is expected to show positive growth, mainly attributed to increased incidence and the expected launch of novel therapies, such as Anlotinib (Advenchen Laboratories), ADP-A2M4: (Adaptimmune Therapeutics) and others during the forecast period (2023-2032) . The pharmacotherapy space is witnessing the development of an antitumor agent like Trabectedin, which is sold under the trade name YONDELIS (Pharma Mar SA/Johnson and Johnson) and a tyrosine kinase inhibitor (TKI) like Pazopanib sold under the brand name VOTRIENT (Novartis Pharmaceuticals). Several other drugs are in pipeline like Anlotinib (Advenchen Laboratories), ADP-A2M4 (Adaptimmune Therapeutics), Tazemetostat (Epizyme/IPSEN), TBI-1301 (Takara Bio), and others.

Synovial Sarcoma Market Landscape
The Synovial Sarcoma market landscape is speculated to change in the coming years owing to the launch of several upcoming therapies. Significant amount of research and developmental activities over the past several years have led to the gradual emergence of more effective and less toxic treatment modalities in synovial sarcoma patients. Some of the major players in the global Synovial Sarcoma market in the late phase of clinical development are Advenchen Laboratories, Adaptimmune Therapeutics, Epizyme/IPSEN, Takara Bio, and others.

Learn more about the FDA-approved drugs for Synovial Sarcoma @ Drugs for Synovial Sarcoma Treatment- https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Synovial Sarcoma Marketed Drugs
• TECELRA (afamitresgene autoleucel): Adaptimmune Therapeutics
TECELRA (afami-cel; formerly ADP-A2M4) is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic Synovial Sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. In August 2024, Adaptimmune Therapeutics received the US FDA accelerated approval of TECELRA for the treatment of adults with unresectable or metastatic Synovial Sarcoma. The approval of TECELRA was based on results of the SPEARHEAD-1 (Cohort 1) trial. TECELRA treatment resulted in an ORR of 43% with a complete response rate of 4.5%.

Synovial Sarcoma Emerging Drugs
• Letetresgene autoleucel (lete-cel): Adaptimmune Therapeutics
Letetresgene autoleucel is an engineered TCR T-cell therapy targeting the solid tumor antigen NY-ESO-1. Lete-cel is being investigated for the treatment of Synovial Sarcoma and myxoid/round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO (NCT03967223) trial in patients who received prior anthracycline treatment. Sponsorship of the ongoing clinical trials for lete-cel has transitioned from GSK to Adaptimmune. The IGNYTE-ESO trial, which is ongoing but no longer open for new participants, has had its interim analysis data presented at CTOS in 2023 also reported data for sub-study 1 of the IGNYTE-ESO trial which explores lete-cel in the first-line setting for treatment naïve patients with metastatic or unresectable Synovial Sarcoma or MRCLS.

• AL3818 (anlotinib): Advenchen Laboratories
AL3818 is an orally administered receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). AL3818 is being evaluated for the treatment of alveolar soft part sarcoma, leiomyosarcoma, and Synovial Sarcoma in a global Phase III trial. It is being developed by Advenchen Laboratories. The FDA and EMA granted AL3818 an orphan drug designation for the potential treatment of soft tissue sarcomas.

Discover more about Synovial Sarcoma Drugs in development @ Synovial Sarcoma Pipeline Drugs Assessment- https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Synovial Sarcoma Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Synovial Sarcoma Companies- Adaptimmune Therapeutics, Advenchen Laboratories, Takara Bio, OncoTherapy Science, and others
• Synovial Sarcoma Pipeline Therapies- CFT8634, FHD-609, Afamitresgene autoleucel, AL3818, Itacitinib, CAB-AXL-ADC, TP-1287, APX005M, Tazemetostat, and others.
• Synovial Sarcoma Market Dynamics: Synovial Sarcoma Market Drivers and Barriers

Discover more about Synovial Sarcoma Drugs in development @ Synovial Sarcoma Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Synovial Sarcoma Executive Summary
3. Competitive Intelligence Analysis for Synovial Sarcoma
4. Synovial Sarcoma: Market Overview at a Glance
5. Synovial Sarcoma: Disease Background and Overview
6. Synovial Sarcoma Patient Journey
7. Synovial Sarcoma Epidemiology and Patient Population
8. Synovial Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Synovial Sarcoma Unmet Needs
10. Key Endpoints of Synovial Sarcoma Treatment
11. Synovial Sarcoma Marketed Products
12. Synovial Sarcoma Emerging Therapies
13. Synovial Sarcoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Synovial Sarcoma Market Outlook
16. Synovial Sarcoma Market Access and Reimbursement Overview of Synovial Sarcoma
17. Synovial Sarcoma KOL Views
18. Synovial Sarcoma Market Drivers
19. Synovial Sarcoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

Autosomal Dominant Polycystic Kidney Disease Market- https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market
Familial Lipoprotein Lipase Deficiency Pipeline- https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-pipeline-insight
Frontotemporal Dementia Pipeline- https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight
Human Papillomavirus-positive Oropharyngeal Cancer Market- https://www.delveinsight.com/report-store/human-papillomavirus-positive-oropharyngeal-cancer-market
Moderate And Severe Chronic Kidney Disease Market- https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market
Monoclonal Gammopathy Of Undetermined Significance Market- https://www.delveinsight.com/report-store/monoclonal-gammopathy-of-undetermined-significance-market
Myopia Treatment Devices Market- https://www.delveinsight.com/report-store/myopia-treatment-devices-market
Myotonic Dystrophy Market- https://www.delveinsight.com/report-store/myotonic-dystrophy-market
Neurodermatitis Market- https://www.delveinsight.com/report-store/neurodermatitis-market
Osteochondrodysplasia Market- https://www.delveinsight.com/report-store/osteochondrodysplasia-market
Peptic Ulcer Hemorrhage Market- https://www.delveinsight.com/report-store/peptic-ulcer-hemorrhage-market
Perivascular Epithelioid Cell Tumor Market- https://www.delveinsight.com/report-store/perivascular-epithelioid-cell-tumor-market
Plasmodium Vivax Malaria Market- https://www.delveinsight.com/report-store/plasmodium-vivax-malaria-market
Thymidine Kinase 2 Deficiency Market- https://www.delveinsight.com/report-store/thymidine-kinase-2-deficiency-tk2d-market
Xlinked Severe Combined Immunodeficiency Market- https://www.delveinsight.com/report-store/xlinked-severe-combined-immunodeficiency-scid-market
Chagas Disease Market - https://www.delveinsight.com/report-store/chagas-disease-market
Diabetes Insipidus Market- https://www.delveinsight.com/report-store/diabetes-insipidus-market
Geographic Atrophy Market- https://www.delveinsight.com/report-store/geographic-atrophy-ga-market
Peanut Allergy Market Report- https://www.delveinsight.com/report-store/peanut-allergy-market
Postherpetic Neuralgia Market- https://www.delveinsight.com/report-store/postherpetic-neuralgia-market
Pouchitis Market- https://www.delveinsight.com/report-store/pouchitis-market
Presbyopia Market- https://www.delveinsight.com/report-store/presbyopia-market
Prostate Cancer Market- https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Refractory Metastatic Melanoma Market- https://www.delveinsight.com/report-store/refractory-metastatic-melanoma-market
Rubella Market- https://www.delveinsight.com/report-store/rubella-market
Smoking Cessation And Nicotine Addiction Market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Systemic Inflammatory Response Syndrome Market- https://www.delveinsight.com/report-store/systemic-inflammatory-response-syndrome-market
Systemic Inflammatory Response Syndrome Market Insights- https://www.delveinsight.com/report-store/systemic-inflammatory-response-syndrome-market
Uveal Melanoma Market- https://www.delveinsight.com/report-store/ocular-melanoma-market
Wiskott-aldrich Syndrome Market- https://www.delveinsight.com/report-store/wiskott-aldrich-syndrome-market
Adult T-cell Leukemia-lymphoma Market- https://www.delveinsight.com/report-store/adult-t-cell-leukemia-lymphoma-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market
House Dust Mite Allergy Market- https://www.delveinsight.com/report-store/house-dust-mite-allergy-market
Immune Thrombocytopenia Market- https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Keloid Market- https://www.delveinsight.com/report-store/keloid-market
Pcsk9 Market- https://www.delveinsight.com/report-store/pcsk9-inhibitors-psck9i-market
Peripheral Nerve Repair Devices Market- https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market
Sarcopenia Market- https://www.delveinsight.com/report-store/sarcopenia-market
Skin Neoplasm Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Vascular Imaging Devices Market- https://www.delveinsight.com/report-store/vascular-imaging-market-market
Venous Ulcer Market- https://www.delveinsight.com/report-store/venous-leg-ulcer-market
Cardiogenic Shock Market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Herpes Labialis Market- https://www.delveinsight.com/report-store/herpes-labialis-market
Meningococcal Meningitis Market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
Septic Shock Market- https://www.delveinsight.com/report-store/septic-shock-market
Transmucosal Drug Delivery Devices Market- https://www.delveinsight.com/report-store/transmucosal-drug-delivery-devices-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
Cone Rod Dystrophy Market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
Orthopedic Power Devices Market- https://www.delveinsight.com/report-store/orthopedic-power-devices-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Diabetic Retinopathy Market- https://www.delveinsight.com/report-store/diabetic-retinopathy-market
Hydrocephalus Treatment Market- https://www.delveinsight.com/report-store/hydrocephalus-market
Short Bowel Syndrome Drug Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Spinal Trauma Devices Market- https://www.delveinsight.com/report-store/spinal-trauma-devices-market-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Tcr Therapy Market- https://www.delveinsight.com/report-store/tcr-therapy-market
Heart Failure Market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.